Cancer type

Colorectal and GI

Colorectal, gastroesophageal, pancreatic, and hepatobiliary cancers, with weight on ctDNA after resection.

All Colorectal Gastroesophageal Pancreatic

Jun 1, 2025GI Pancreatic MRD / ctDNA Trials

ADAPT-MRD opens a randomized comparison of ctDNA-guided adjuvant therapy after pancreatic resection

ClinicalTrials.gov lists ADAPT-MRD (NCT06966440) as a recruiting randomized trial that started June 1, 2025, assigning patients after resection of pancreatic cancer to ctDNA-guided adjuvant therapy or standard adjuvant therapy.

ClinicalTrials.gov

ASCO 2025GI Pancreatic MRD / ctDNA Conference data

Resected pancreatic cancer: landmark ctDNA positivity was associated with earlier recurrence

An ASCO 2025 interim analysis of 112 patients with resected stage I to III pancreatic adenocarcinoma reported that landmark postoperative ctDNA positivity predicted recurrence (HR 2.39; 95% CI 1.14 to 5.01), and longitudinal positivity was associated with shorter disease-free survival (HR 3.13).

Journal of Clinical Oncology